echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Murray announced: Vice Chairman, General Manager replacement

    Murray announced: Vice Chairman, General Manager replacement

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wen: Mick vice chairman, general manager change November 17-18, Murray Medical issued a number of official announcements, announced the vice chairman, senior management changes, as well as centralized volume procurement on the company's business impact and other news.
    the announcement, according to the articles of association of the company, Murray Medical held the eighth meeting of the 7th board of directors, considered and adopted the "on the election of the company's seventh board of directors vice chairman of the bill" and "on the appointment of the company's general manager of the bill."
    the board of directors elected Cheng Ming and as vice chairman of the company, and still serves as the strategic committee, audit committee and remuneration and appraisal committee members of the board of directors of the company, and no longer serves as general manager of the company; At the same time, the board of directors of the company appointed Wu Wei as the general manager of the company.
    term of office shall be from the date of consideration and adoption by the current board of directors to the end of the term of office of the current board of directors.
    independent directors of the company have expressed their consent to the relevant matters.
    Cymru Blue Device learned from the Murray Announcement that Cheng Ming and, born in 1961, were of Chinese (Hong Kong) nationality.
    graduated from Shanghai Jiaojiao University with a bachelor's and master's degree in biomedical engineering.
    is currently a director and general manager of Murray Medical and one of the founders of Murray Healthcare.
    Chengming and worked for Shenzhen Anke High Technology Co., Ltd. from 1988 to 1991.
    served as Vice President of Meirui Electronics from 1991 to 1997 and Vice President of Shenzhen Redou Instruments Co., Ltd. from 1998 to 2000, and has served as Vice President of Marketing, Executive Vice President of Strategic Development, Chief Strategy Officer, Co-CEO, etc. since 2000.
    , born in 1972, has Chinese nationality and no permanent residence abroad.
    graduated from Guanghua School of Management, Peking University, with a Master of Business Administration degree in Senior Management.
    is currently a director and executive vice president of Murray Medical.
    from 1995 to 1999, he worked for Meirui Electronics, and since 1999 he has served as Deputy Manager of Meirui Medical Region, Director of Sales of Domestic Marketing Systems, Deputy General Manager, Vice President, Senior Vice President, Executive Vice President, etc.
    the reasons for the replacement, Murray Medical also provided an explanation and explanation.
    Mari pointed out that by the impact of the global outbreak, Murray from within the enterprise began to change to cope with the environment, any enterprise development to a certain extent, want to be bigger and stronger, the key lies in system construction and management echelon construction.
    Mari participated in this kind of belt procurement november 15, according to the Qilu Evening News, November 14, Zibo - Qingdao - Dongying - Yantai - Weihai - Binzhou - Texas seven city procurement alliance supplies belt procurement completed the bargaining.
    in this negotiation price reduction of the armed enterprises, There is Wuhan Meirui Technology Co. , Ltd. to choose the myelin nail system-related products.
    in this regard, Murray pointed out that the current national health insurance bureau to promote the collection is mainly for drugs and high-value supplies field, the company's three lines of business products are not involved in drugs and high-value supplies, other products in orthopaedic supplies, because the proportion of income is very small, so the company's business has no impact at present.
    As analyzed from the perspective of potential future impact, medical equipment as the cost item of the hospital, not the income item, the hospital is the main body of natural cost reduction, so medical equipment does not belong to the national medical insurance bureau to implement the collection of objects.
    the same time, because medical equipment has a wide variety of models, specialized applications, rapid product iteration and so on, the implementation of collection is more difficult.
    at present, the areas laid out by Murray are essential to enhance the ability of a general hospital medical services, so even under the premise of hospital control fees will not reduce equipment procurement, but will increase the procurement of cost-effective domestic products.
    For the field of reagents for in-body diagnosis, the implementation of collecting is still difficult due to the characteristics of high technical barriers, differentiated competition, the dominant market position of imported brands, and closed systems for instruments and reagents.
    At the same time in some of the market capacity of larger areas such as in-body diagnostic production line of chemical luminescence, medical imaging production line color super, whether from the technical or market share, domestic brands are still catching up with imported brands stage, from the product performance point of view, domestic brands alone can not fully cover all the needs of the client, especially high-end and even ultra-high-end product demand.
    , price as the decision-making criteria for procurement may lead to low-cost winning products that ultimately fail to meet clinical needs.
    : The state will accelerate the full implementation of DRGs for the future trend of the domestic medical ecology, Murray also made a judgment.
    , DRGs will be a more effective way to ease financial pressures on health care and reverse the pressure on equipment suppliers to lower product prices, the company said in a statement.
    the outbreak increases financial and health-care funding pressures on hospitals, the state will accelerate the full implementation of DRGs.
    DRGs involves the synergy and coordination of multidisciplinary departments in hospitals, and cost-effective products will further replace imports.
    At the same time, on the question of whether the accelerated market-oriented promotion of the new crown vaccine will affect the growth momentum of enterprises in the future, Mei Rui said that from the income ratio structure, including monitors, ventilators, infusion pumps, portable ultrasound and other products driven by the demand of the epidemic significantly less than 30% of the historical income, but showed explosive growth, making up for the remaining more than 70% of the business by the negative impact of the epidemic performance.
    if the global outbreak is effectively brought under control after the vaccine is launched, more than 70% of Murray's damaged business will be able to recover, which will lead to rebounding business growth.
    Although the new crown vaccine has not yet been widely available in the domestic market, but thanks to the good control of the domestic epidemic, affected by the outbreak performance of the weak business, such as the proportion of domestic revenue of the larger in-body diagnostic business and desktop ultrasound business, from the third quarter has shown a good recovery momentum, some emerging businesses such as hard mirror system, AED in the third quarter have recovered to more than double the high-speed growth, so that the domestic market as a whole showed an accelerated recovery trend.
    of the international market is still at the peak of the epidemic, and did not see a clear inflection point, once the European and American vaccines effectively launched and popularized, the high probability will be effectively controlled the outbreak.
    the global economy, particularly in emerging markets with greater growth potential, emerging markets are expected to take over as new growth drivers in the long term.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.